Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Elevance Health Inc

It's difficult to imagine a future where healthcare isn't in high demand.

Wall Street Thinks These 2 Blazing Healthcare Stocks Could Have 21% to 30% Upside in 2023

PARIS , Jan. 18, 2023 /PRNewswire/ -- Sanofi announces at the 53rd Annual Meeting of the World Economic Forum in Davos the launch of the Sanofi NextGen Scholarship, its first global higher education scholarship program for people from numerous communities underrepresented in healthcare professions. The program will help pay tuition and other expenses at institutions of higher education for students who are part of their nation's ethnic minority groups, women, people with disabilities and members of the LGBTQ+ community who wish to pursue careers as doctors, nurses, scientists, researchers and other healthcare-related professions.

Sanofi launches first global scholarship program for students from underrepresented communities pursuing careers in healthcare

Novo Nordisk

SNY vs. NVO: Which Stock Is the Better Value Option?

Eli Lilly

The lawsuit aims to curb the skyrocketing cost of insulin charged by insulin manufacturers and pharmacy benefit managers companies. The State also seeks to recover some monetary compensation.

State of California Sues Insulin Makers for Unfair Practices

Sanofi Ventures announces multi-year capital commitment from Sanofi, increasing evergreen fund to $750M

Press Release: Sanofi Ventures announces multi-year capital commitment from Sanofi, increasing evergreen fund to $750M

Sanofi SA (NASDAQ:SNY ) 41st Annual J.P. Morgan Healthcare Conference January 10, 2023 1:30 PM ET Company Participants Paul Hudson - CEO Conference Call Participants Richard Vosser - JPMorgan Richard Vosser Welcome to the Sanofi presentation at the 41st JPMorgan Healthcare Conference.

Sanofi SA (SNY) CEO Paul Hudson Presents at 41st Annual J.P. Morgan Healthcare Conference (Transcript)

Bayer AG

CAMBRIDGE, Mass. & LEVERKUSEN, Germany--( BUSINESS WIRE )--NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. The financing will be used to advance NextPoint's two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses.

NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs

AbbVie

Amgen

AstraZeneca

Bristol-Myers

Johnson & Johnson

Merck

Novartis

Pfizer

Roche Holding AG

The pipeline is the heart of a drug discovery company. As such, analyzing the health of a pipeline can lead to suggestions about future performance.

Ranking The Top 10 Pharmaceuticals By Pipeline

This star drug for Sanofi is one step closer to approval in the European Union for another chronic inflammatory disease.

What This Drug News Could Mean for Sanofi Shareholders

FDA accepts nirsevimab application as first protective option against RSV disease for all infants

Press Release: FDA accepts nirsevimab application as first protective option against RSV disease for all infants

Availability of the Q4 Memorandum for modelling purposes

Press Release: Availability of the Q4 2022 Memorandum for modelling purposes

BioNTech SE

GlaxoSmithKline

Here we discuss three big drug and biotech companies, Sanofi (SNY), GSK (GSK) and BioNTech (BNTX), which may prove to be good bets for your portfolio next year.

3 Big Drug, Biotech Stocks to Boost Your Portfolio in 2023

One can invest in Sanofi (SNY) due to the strong performance of Dupixent, above-market sales growth of the Consumer unit, consistent pipeline innovation and regular accretive collaboration deals.

Sanofi's (SNY) Dupixent & Vaccines Make the Stock Attractive

Medtronic

Medical Properties Trust

These three offer high dividend yields and consistent revenue growth.

3 Medical Dividend Stocks That Hit the Sweet Spot

P ositive Dupixent ® (dupilumab) P hase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine

Press Release: Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine

Sanofi's SARS-CoV-2 spike protein (B.1.351 strain) vaccine, (VidPrevtyn® Beta) is the first and only Beta variant protein-based COVID-19 booster approved in Great Britain and the European Union

MHRA authorises VidPrevtyn® Beta▼ in Great Britain, Sanofi's COVID-19 booster vaccine

Moderna

With economic worries unsettling investors, it is not surprising that leading advisors, and contributors to MoneyShow.com, are looking to the pharmaceutical sector – Here's a look at seven global favorites, focused on such areas as obesity and diabetes to new applications for mRNA-based vaccines.

7 Healthy Buys Among Global Drug Makers

The CHMP recommends approval of Sanofi (SNY) and partner Regeneron's Dupixent for the treatment of adults and adolescents with eosinophilic esophagitis.

Sanofi (SNY) Dupixent Gets CHMP Nod to Eosinophilic Esophagitis

Innate Pharma SA

Shares of Innate Pharma SA ADR [S: ipha] rallied 35.2% in premarket trading on Monday after the company said Sanofi SNY, -0.38% licensed its natural killer (NK) cell engager program as part of an already established collaboration between the two companies. "We are exploring the potential of NK cells for cancer immunotherapy, a key pillar for our oncology strategy," Valeria Fantin, Sanofi's global head of oncology research, said in a news release.

Innate, Sanofi ink licensing deal for NK cells

Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology

Press Release: Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology

MARSEILLE, France--( BUSINESS WIRE )--Regulatory News:

Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology

Dupixent ® (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esop hag itis

Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis

United Continental Hlds

Ulta Beauty

United Therapeutics

Given the prevailing challenges in the market, investors can consider momentum stocks like SNY, GSK, ULTA, UAL and UTHR to get handsome returns in the near term.

5 Momentum Stock Bargains Hunters Would Love Chasing

The EC approves Sanofi (SNY) and its partner Regeneron's Dupixent for the treatment of adult patients with prurigo nodularis.

Sanofi's (SNY) Dupixent Gets Europe Nod for Prurigo Nodularis

Dupixent ® (dupilumab) a pproved by European Commission as the f irst and o nly t argeted m edicine i ndicated for p rurigo n odularis

News for Sanofi Stock (SNY)